These sophisticated models are still in their relative infancy with many caveats attached to their use, such as poor reconstitution of certain immune cell compartments, differing MHC between stem cell donor and tumor graft and development of graft versus host disease58,59, but they are potentially very promising models for future evaluation and comparison with established murine models. The gene discussed is HLA-C; the disease is neoplasm.